American Bio Medica Corporation
ABMC · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.07 | -0.81 | 0.09 |
| FCF Yield | -290.80% | -41.97% | -10.54% | 2.55% |
| EV / EBITDA | -2.12 | -15.42 | -11.86 | -11.30 |
| Quality | ||||
| ROIC | 1,254.55% | -175.45% | -99.84% | -72.14% |
| Gross Margin | -21.14% | 24.71% | 29.85% | 32.39% |
| Cash Conversion Ratio | 0.54 | 1.45 | 0.61 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.62% | -15.34% | 2.31% | -9.40% |
| Free Cash Flow Growth | -14.12% | -38.19% | -939.66% | 123.97% |
| Safety | ||||
| Net Debt / EBITDA | -1.90 | -7.37 | -3.30 | -4.60 |
| Interest Coverage | -6.40 | -6.08 | -3.55 | -2.24 |
| Efficiency | ||||
| Inventory Turnover | 2.92 | 3.77 | 5.43 | 3.05 |
| Cash Conversion Cycle | -12.20 | 66.74 | 30.68 | 60.29 |